Streetbeat News

Regulatory

EPIX

PFE

ESSA Pharma Inc. (NASDAQ:EPIX) has decided to terminate its Phase 2 trial of masofaniten combined with enzalutamide for prostate cancer due to insufficient efficacy. The trial showed a higher PSA90 response rate with Pfizer's Xtandi monotherapy, leading to a futility analysis indicating a low likelihood of meeting the study's primary endpoint. ESSA plans to focus resources elsewhere, ending other studies involving masofaniten. EPIX stock fell 69.80% in premarket trading.

Portfolio Pulse from Vandana Singh

November 01, 2024 | 1:28 pm

JPM

JPMorgan Chase & Co. is set to pay over $151 million in penalties and voluntary payments after the SEC charged its affiliates with various law violations, including misleading disclosures and breach of fiduciary duty.

Portfolio Pulse from Erica Kollmann

November 01, 2024 | 1:20 pm

LLY

NVO

Novo Nordisk's weight loss drug Wegovy shows promising results in a liver fibrosis trial, achieving primary endpoints with significant improvements. The company plans to seek regulatory approvals in 2025. The FDA has updated its shortage list, noting the availability of Wegovy's starter dose.

Portfolio Pulse from Vandana Singh

November 01, 2024 | 1:12 pm

FXI

SPY

China's Commerce Ministry has revised measures to allow foreign individuals to make strategic investments in listed companies. This move could impact foreign investment in Chinese markets.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 1:09 pm

AMZN

ARM

GOOGL

MSFT

NVDA

Nvidia's acquisition of Run:ai is under scrutiny by the European Commission due to competition concerns in the AI and data center markets. The acquisition, valued at $600-$700 million, could impact competition in the European Economic Area. Nvidia's dominance in AI chips is also being investigated by U.S. antitrust authorities.

Portfolio Pulse from Anusuya Lahiri

November 01, 2024 | 1:06 pm

LXRX

SNY

VTRS

The FDA's advisory committee voted against Lexicon Pharmaceuticals' Zynquista for type 1 diabetes, citing that the benefits do not outweigh the risks. Despite this, Lexicon plans to resubmit the NDA and anticipates a potential launch in early 2025. The stock price of Lexicon Pharmaceuticals dropped significantly following the news.

Portfolio Pulse from Vandana Singh

November 01, 2024 | 1:05 pm

FGFPP

Trading for FGFPP was halted and has now resumed as of 9:00:00 AM ET. The halt was due to pending news, and trading has now resumed following the release of this information.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 1:00 pm

FGF

Trading for FGF was halted and has now resumed as of 8:55:00 AM ET. The halt was due to pending news, and trading has now resumed following the release of this information.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 12:55 pm

FEMY

Femasys Inc has been granted a US patent for FemBloc, a permanent birth control product, with the patent set to expire in 2039.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 12:34 pm

AAUKF

BHP

BHP has clarified that its chairman's comments about moving on from the failed $49 billion bid for Anglo American were not a formal withdrawal. The UK Takeover Panel confirmed that BHP's remarks do not constitute an official 'no offer' statement, leaving the door open for a future bid. BHP is focusing on expanding its operations in South America and addressing labor issues in Australia.

Portfolio Pulse from Stjepan Kalinic

November 01, 2024 | 12:29 pm